Crossmark

Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT)

Crossref DOI link: https://doi.org/10.1186/s12916-026-04781-4

Published Online: 2026-03-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Maohui

Huang, Yizhou

Zhang, Shuliang

Chen, Cheng

Zeng, Taidui

Li, Hongmu

Yang, Zhenyuan

Lin, Chuanquan

Li, Wei

Xu, Benhua

Chen, Chun

Zheng, Bin
Funding

Funding for this research was provided by:

Clinical Research Center for Thoracic Tumors of Fujian Province (2024YGPT001)

Fujian Province's special financial funds (2023CZ001)
License Information

Text and Data Mining valid from 2026-03-09

Version of Record valid from 2026-04-15
More Information

Article History

Received: 30 December 2025

Accepted: 4 March 2026

First Online: 9 March 2026

Declarations

:

: This trial was conducted at Fujian Medical University Union Hospital following approval from the institutional ethics board (No. 2021YF040-01). The study was conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided written informed consent to participate prior to enrollment. The trial was registered at ClinicalTrials.gov (NCT05176002) prior to patient recruitment.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below